Shares at $60.33: Novo Nordisk (NVO, NYSE) After Hours 30 Jan 2026, earnings ahead
NVO stock trades at $60.33 in after-hours action on 30 Jan 2026 as investors position ahead of an earnings report due 04 Feb 2026. The stock opened $61.48 today and closed at $59.33 before after-hours moves. Novo Nordisk A/S (NVO) listed on the NYSE in the United States carries a PE 15.85 and EPS 3.75, metrics investors will watch in the coming report. Volume today reached 16,235,907 shares versus an average of 22,784,462. Meyka AI provides model-based context for the near-term outlook and a proprietary grade below.
NVO stock: after-hours price action and liquidity
NVO stock is trading $60.33 after hours on the NYSE following a regular session high of $61.56 and low of $59.99. Today’s volume totaled 16,235,907 shares compared with an average volume of 22,784,462, signaling lighter liquidity in directional moves. The stock remains well below its 52-week high $93.80 and above the 52-week low $43.08, leaving a wide range for traders.
NVO stock: earnings timeline and what to expect
Novo Nordisk A/S has an earnings announcement scheduled for 04 Feb 2026 at 08:30 ET. Analysts will focus on Diabetes and Obesity Care revenue and margin trends, plus guidance for 2026. Street sentiment shows 4 Buys, 11 Holds and 4 Sells (consensus score 3.00), so the market expects mixed commentary rather than a unanimous beat.
NVO stock: fundamentals and valuation snapshot
Novo Nordisk A/S shows EPS 3.75 and PE 15.85, with market capitalization about $264.21B on the NYSE in the United States. Price averages sit at 50-day $52.77 and 200-day $58.90, indicating the stock is above the longer-term mean. Key ratios include dividend yield 2.07%, return on equity 66.95%, and debt-to-equity 0.60, painting a profitable but capital-intensive profile.
NVO stock: technical and trading signals
Technicals show momentum to the upside but near-term overbought readings: RSI 75.83, MACD histogram 0.88, and ADX 29.50 indicating a strong trend. Bollinger bands center at $51.90 with an upper band $58.43, suggesting current price sits above the upper band. Short-term traders should note ATR 1.79 and relative volume under 1 at 0.51, which can compress moves around earnings.
NVO stock: news flow and market context
Recent coverage includes real-time quotes and company updates from major outlets; see coverage on CNBC and broader markets reporting on Reuters. Sector context matters: the Healthcare sector has been outperforming defensives this year, but drugmakers face scrutiny on pricing and product concentration, which can affect Novo Nordisk’s trading on earnings.
NVO stock: Meyka AI grade and scenario valuation
Meyka AI rates NVO with a score out of 100: 74.40 — Grade B+, Suggestion: BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. The company shows strong profitability metrics but higher price-to-book and long-term debt growth; these trade-offs inform the grade. This assessment is informational. These grades are not guaranteed and we are not financial advisors.
Final Thoughts
Key takeaways for NVO stock: Novo Nordisk trades $60.33 after hours as the market waits for the 04 Feb 2026 earnings release. Fundamentals are strong with EPS 3.75 and PE 15.85, while technicals show overbought conditions (RSI 75.83). Meyka AI’s forecast model projects a near-term monthly price of $62.44, an implied upside of 3.50% versus the current $60.33, and a quarterly scenario at $48.85, implying a downside of -19.03%. Our model-based outlook and the Meyka grade (74.40, B+, BUY) point to cautious optimism ahead of earnings, but volatility is likely. Use earnings detail, margin commentary and guidance as your price drivers. Forecasts are model-based projections and not guarantees.
FAQs
When will NVO stock report earnings and why does it matter?
Novo Nordisk will report on 04 Feb 2026 at 08:30 ET. The report matters because revenue and margin detail in Diabetes and Obesity Care will drive near-term guidance and stock reaction.
What is the current valuation for NVO stock?
NVO stock trades at PE 15.85 with EPS 3.75 and market cap around $264.21B on the NYSE. These figures help compare valuation to peers and to growth expectations.
How does Meyka AI view NVO stock near term?
Meyka AI’s forecast model projects a monthly price $62.44 (implied upside 3.50%) and assigns a grade B+ (74.40). Models are projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
